Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + lenvatinib + chemotherapy versus pembrolizumab + chemotherapy as first-line treatment for metastatic esophageal squamous cell carcinoma
CTR20213019Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab, lenvatinib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Merck & Co.. Started Dec 2021; status: terminated.
02
Drugs
pembrolizumablenvatinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20213019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213019.